Cargando…
Degradation Characteristics of a Novel PAF Receptor Antagonist, SY0916, in Aqueous Solution
SY0916 has been proven to be a potent treatment agent against rheumatoid arthritis in preclinical studies and has been shown to be safe in phase I clinical trials. However, SY0916 is unstable in water, which is frequently used in pharmaceutical development processes. The degradation behaviour and st...
Autores principales: | Jin, Bo, Wang, Yanan, Zhang, Tingting, Yin, Wanting, Zhang, Dongfeng, Huang, Haihong, Ma, Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350595/ https://www.ncbi.nlm.nih.gov/pubmed/30766739 http://dx.doi.org/10.1155/2019/8789470 |
Ejemplares similares
-
PAF‐induced inflammatory and immuno‐allergic ophthalmic diseases and their mitigation with PAF receptor antagonists: Cell and nuclear effects
por: Sharif, Najam A.
Publicado: (2022) -
Complete Genome Sequence of Weissella hellenica 0916-4-2 and Its Comparative Genomic Analysis
por: Panthee, Suresh, et al.
Publicado: (2019) -
SP_0916 Is an Arginine Decarboxylase That Catalyzes the Synthesis of Agmatine, Which Is Critical for Capsule Biosynthesis in Streptococcus pneumoniae
por: Ayoola, Moses B., et al.
Publicado: (2020) -
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
por: Kim, Tae Won, et al.
Publicado: (2022) -
Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects
por: Shamizadeh, Soja, et al.
Publicado: (2014)